Referring to the discussion above, one shouldn’t forget that rather than therapy devices, Nexstim’s largest and fastest-growing business segment is in diagnostics, which Brainlab’s sales organization is currently expanding at a solid pace. On the therapy side as well, the market has already opened up significantly outside Finland, so I personally won’t get depressed (pun intended), even though the cost pressures on Finland’s wellbeing services counties are high and investments may be tight.
Therefore, I don’t see any competing treatment displacing Nexstim’s therapy devices in the near future at least, and I remain confident in the company. In the future, I expect entirely new market openings through Brainlab, and I especially hope for Sinaptica’s success, which I believe would be the biggest catalyst. If nothing substantially changes in the story, I will happily continue putting my pennies into the company’s shares going forward.